Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

Published:2015-12 Issue:3 Volume:90 Page:534-541
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gerber David E.,Boothman David A.,Fattah Farjana J.,Dong Ying,Zhu Hong,Skelton Rachel A.,Priddy Laurin L.,Vo Peggy,Dowell Jonathan E.,Sarode Venetia,Leff Richard,Meek Claudia,Xie Yang,Schiller Joan H.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit. Rev. Oncol. Hematol.,1995

2. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival;Veale;Br. J. Cancer,1993

3. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer;Fujino;Eur. J. Cancer,1996

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC);Cancer Pathogenesis and Therapy;2024-07

2. DDCM: A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm;International Journal of Molecular Sciences;2024-05-12

3. Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer;International Journal of Molecular Sciences;2024-02-08

4. Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer;Recent Patents on Anti-Cancer Drug Discovery;2023-11

5. Cancer cell plasticity during tumor progression, metastasis and response to therapy;Nature Cancer;2023-08-03